Biovail, GSK Accused of Generic Wellbutrin Delay

An employee benefit plan has filed a motion to certify a class action against Biovail and GlaxoSmithKline (GSK), alleging the companies conspired to delay entry of a generic form of the antidepressant Wellbutrin XL. The plaintiffs allege that Biovail and GSK maintained exclusivity of Wellbutrin XL (bupropion HCl) by filing baseless patent infringement suits against four drugmakers — Anchen Pharmaceuticals, Impax Laboratories, Watson Pharmaceuticals and Abrika Pharmaceuticals, which is now part of Actavis — for filing ANDAs for generic Wellbutrin XL.
Washington Drug Letter